Henry Haiser
Operating Partner Corundum Systems Biology
Henry Haiser is Operating Partner at Corundum Systems Biology, where he leads scientific and strategic diligence across microbiome and systems biology investments. He works closely with portfolio companies to guide R&D strategy, biomarker development, and platform innovation, helping translate emerging science into impactful products and therapies. Henry also leads scientific landscaping and venture creation efforts, collaborating with founders and academic researchers to identify high-potential opportunities and shape investment theses in next-generation biotechnology.
Seminars
- Defining core investment checklists used by generalist biotech VCs to assess microbiome opportunities, enabling alignment of narratives with decision drivers
- Diagnosing causes of investor skepticism following early company failures to reposition data packages, risk profiles, and timelines for renewed confidence
- Attracting non-specialist venture investors by translating complex biology into clear value propositions and commercial milestones to expand the capital pool
Pharma skepticism towards microbiome therapeutics, driven by past clinical failures and difficulty distinguishing robust science, has delayed partnership engagement until Phase II data. This workshop outlines how to package mechanistic insight and early clinical evidence to meet pharma expectations and unlock earlier, higher-quality partnering conversations.
Workshop highlights:
- Structuring differentiated mechanism-of-action narratives using immune, metabolic, and microbial pathways to position programs in language that resonates with pharma decision-makers.
- Aligning early clinical study design with pharma-preferred endpoints and indications to generate signals that support future regulatory and commercial success
- Positioning Phase I, translational, and biomarker datasets strategically to maintain engagement and credibility despite limited late-stage outcome data availability
- Demonstrating scientific validation across heterogeneous microbiome approaches to clearly separate high-quality programs from lower-confidence competitors in crowded pipelines
